The investigators seek to derive and validate a clinically useful risk score for patients with Coronavirus Disease 2019 to aide clinicians in the safe discharge of patients.

The investigators a-priori plan the following analysis:

1. Derivation and Retrospective Validation.

   • Select all adult patients with a positive reverse transcription polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 beginning March 1, 2020 until approximately 1000 patients are included.
   • Use 75% of this cohort to develop a simple risk-score that prognosticates a patient's suitability for discharge (no supplemental oxygen, no intensive care unit, and no death). Use multivariable logistic regression with forward selection informed by clinical judgement to choose variables a priori that emphasizes readily available data and easy calculation for use at the point of care.
   • Use 25% of this cohort to retrospectively validate the risk-score.

2. Prospective Validation.

   • Select all adult patients with a positive reverse transcription polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 as soon as the derivation cohort in step 1 is assembled. Include approximately 250 patients.
   • Use this sample to prospectively validate the risk-score developed in part 1.

Inclusion Criteria:

• Positive reverse transcription polymerase chain reaction for severe acute respiratory syndrome coronavirus 2
• Age 18 and older

Exclusion Criteria:

• None

The study population includes every adult patient noted positive for severe acute respiratory syndrome coronavirus 2 in the entire Partners HealthCare system, a consortium hospitals and health care entities located in Massachusetts that cares for over 1.5 million patients each year.

Investigators may provide reasonable requests for IPD. These requests will be reviewed by the study team and institution on a case by case basis.